FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.